theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Medical Oncology

Thalassemia   

Questions discussed in this category


What are your top takeaways in Classical Hematology from ASH 2024?
9 Answers available

What is your strategy for optimizing hydroxyurea dosage in patients with symptomatic sickle cell disease, particularly for genotypes HbSS and HbS/Beta thal?
1 Answer available
2248019642


Papers discussed in this category


The New England journal of medicine, 2008-03-27
Hydroxyurea for the treatment of sickle cell anemia.

The New England journal of medicine, 2020 Jun 25
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.

Frontiers in genetics, 2022 Aug 26
Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative.

The New England journal of medicine, 2013-02-21
Apixaban for extended treatment of venous thromboembolism.

The New England journal of medicine, 2017 Mar 18
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Related Topics in Medical Oncology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2025 theMednet
All Rights Reserved.